{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Flow cytometry will be used to characterize the function of immune checkpoint regulators (VISTA, CTLA-4, PD-1) during early immune recovery following an allogeneic stem cell transplant.","groups":[{"description":"Cyclophosphamide, fludarabine, total body irradiation, immune suppression including tacrolimus and cellcept, Granulocyte colony-stimulating factor (G-CSF), and peripheral blood transplant\n\nCyclophosphamide: 14.5 mg/kg for 2 days (days -6, -5) and then 50 mg/kg for two days (days 3, 4)\n\nFludarabine: 30 mg/m2 daily for 5 days\n\nTotal Body Irradiation: 200 centigray (cGy) for one day (day -1)\n\nTacrolimus: 1 mg IV daily, (or the oral equivalent) adjusted to achieve a level between 5 and 15 ng/ml. If there is no evidence of GVHD, discontinue Tacrolimus by Day 180.\n\ncellcept: dose at 15 mg/kg po three times per day (maximum dose of 3 grams/day). Stop Cellcept at Day 35 following transplantation.\n\ng-csf: 5 mcg/kg/d starting day 5 and continue until Absolute Neutrophil Count (ANC) \\> 1000/mcL for 3 days.\n\nPeripheral Blood Transplant: cell dose goal: \\< 5 x 106 Hematopoietic progenitor cell antigen CD34+ cells/kg recipient weight","id":"OG000","title":"Johns Hopkins' Conditioning Regimen"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Blood samples were collected, however laboratory analysis was not performed due to lack of funding. There are no plans to potentially analyze the samples in the future, therefore these samples were not, and will not be, analyzed.","reportingStatus":"POSTED","timeFrame":"Days 30, 60, and 90 post-transplant","title":"Immune Checkpoint Regulators - Function","type":"SECONDARY","unitOfMeasure":"Participants"}